Search
Norfloxacin succinil
go.drugbank.com/drugs/DB20858ExperimentalThe usage of the INN stem '-nil' in the name indicates that Norfloxacin succinil is a benzodiazepine receptor antagonist/agonist. … The usage of the INN stem '-oxacin' in the name indicates that Norfloxacin succinil is a nalidixic acid derivative antibacterial. Norfloxacin succinil has a monoisotopic molecular weight of 419.15 Da.
Thyrotropin alfa
go.drugbank.com/drugs/DB00024ApprovedInvestigationalVet approvedThyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in...
Categories: Sex Hormones and InsulinsRamoplanin
go.drugbank.com/drugs/DB04952ExperimentalRamoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
Temporomandibular Joint Dysfunction
go.drugbank.com/conditions/DBCOND0039544Drugs: Botulinum toxin type ASynonyms: Costen's complexLeptazoline D
go.drugbank.com/drugs/DB15554ExperimentalAlso see [Leptazoline A], [Leptazoline B], and [Leptazoline C].
CSIC002
go.drugbank.com/drugs/DB18584ExperimentalCSIC002 is a small-molecule Sema-3A inhibitor. It is being investigated for the treatment of anterior ischemic optic neuropathy.
Tubulin gamma-1 chain
go.drugbank.com/bio_entities/BE0003713TargetHumansGamma-tubulin is a key component of the gamma-tubulin ring complex (gTuRC) which mediates microtubule nucleation (PubMed:38305685, PubMed:38609661, PubMed:39321809).
Synonyms: Gamma-tubulin complex component 1Bioymifi
go.drugbank.com/drugs/DB17493ExperimentalBioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-depen...
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalAmrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sa...